Table 4.
Univariate cause-specific Cox model for time to CRS/ICANS resolution
| Characteristic | HR1 | 95% CI1 | p-value |
|---|---|---|---|
| CAR T cell Product (axi-cel/brexu-cel vs other) | 0.70 | 0.35, 1.39 | 0.304 |
| Age | 1.00 | 0.98, 1.01 | 0.616 |
| Pre-LD KPS (%) | 1.04 | 1.01, 1.08 | 0.007 |
| Pre-LD Ferritin (log10) | 0.61 | 0.33, 1.12 | 0.112 |
| Pre-LD LDH (log10) | 0.36 | 0.10, 1.27 | 0.111 |
| Pre-LD Albumin (log10) | 0.76 | 0.29, 2.00 | 0.577 |
| Pre-LD Bulky Disease | 0.52 | 0.25, 1.07 | 0.074 |
| CRS or ICANS grade at anakinra initiation | 0.89 | 0.64, 1.23 | 0.468 |
| Time to anakinra initiation from CAR T-cell infusion | 0.98 | 0.90, 1.07 | 0.667 |
| Time to anakinra initiation from CRS/ICANS onset | 0.94 | 0.84, 1.05 | 0.260 |
| Anakinra dose (High vs Low) | 2.19 | 0.94, 5.12 | 0.069 |
| Anakinra daily dose (mg/kg/day) | 1.10 | 0.97, 1.24 | 0.136 |
1
HR = Hazard Ratio, CI = Confidence Interval
Abbreviations: axi-cel, axicabtagene ciloleucel; brexu-cel, brexucabtagene autoleucel ; LDH, lactate dehydrogenase; LD, lymphodepletion; CAR, chimeric antigen receptor ; CRS, cytokine release syndrome, ICANS, Immune effector cell-associated neurotoxicity syndrome; TRM, treatment-related mortality